Danish biotech company still considers IPO
It has been a great fiscal year for Nuevolution, but the ambitious company is nevertheless on the prowl for capital with an IPO lurking on the horizon.
BY STEFAN SINGH KAILAY
Denmark’s Nuevolution has gone from a deficit of DKK 32.43 million to a profit of DKK 6.24 million in its latest fiscal year, which must be seen as a massive success for the small biotech outfit. But the company is nevertheless hunting for capital, says Chairman Stig Løkke Pedersen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Nuevolution continues hiring round
For abonnenter
Nuevolution brings in prominent board member
For abonnenter
Nuevolution strikes deal with Swiss pharma giant
For abonnenter
